



**HAL**  
open science

## Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study

Emmanuel Deshayes, Hélène de Forges, Julien Fraisse, Marie-Claude Eberlé, Sophie Guillemard, Anne Fallières, Jean-Pierre Pouget, Raphaël Tetreau, Pierre-Olivier Kotzki, Lore Santoro, et al.

### ► To cite this version:

Emmanuel Deshayes, Hélène de Forges, Julien Fraisse, Marie-Claude Eberlé, Sophie Guillemard, et al.. Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study. *Clinical Nutrition*, 2018, 10.1016/j.clnu.2018.08.033 . hal-02285810

HAL Id: hal-02285810

<https://hal.umontpellier.fr/hal-02285810>

Submitted on 20 Jul 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



26 **Abstract**

27 ***Background and Aims***

28 Nutrition support is recommended in cachexic patients with cancer. However, there is no clear  
29 evidence about its impact on tumour growth. Glycolysis, which is usually higher in cancer than normal  
30 cells, can be monitored by  $^{18}\text{F}$ -fluorodeoxyglucose positron emission tomography/computed  
31 tomography ( $^{18}\text{F}$ -FDG PET/CT) imaging that is widely used for cancer staging and therapy efficacy  
32 assessment. Here, we used  $^{18}\text{F}$ -FDG PET/CT imaging to investigate whether artificial nutrition has an  
33 impact on tumour glucose metabolism in patients with cancer and cachexia.

34 ***Methods***

35 This prospective study included ten patients with histologically proven head and neck or oesophageal  
36 cancer. All patients underwent  $^{18}\text{F}$ -FDG PET/CT imaging at baseline and after (parenteral and/or  
37 enteral) nutrition support on average for 7 days. Tumour glucose metabolism changes were evaluated  
38 using static ( $\text{SUV}_{\text{max}}$ ,  $\text{SUV}_{\text{mean}}$  and  $\text{SUL}_{\text{peak}}$ ) and dynamic (glucose metabolic rate and transport  
39 constant rates,  $k$ ) parameters computed from the  $^{18}\text{F}$ -FDG PET/CT data.

40 ***Results***

41 Artificial nutrition (median energy intake of 21.83 kcal/kg/day [13.16-45.90], protein intake of 0.84  
42 g/kg/day [0.56-1.64]) was administered. Eight patients (80%) received enteral nutrition and two  
43 patients (20%) parenteral support. Comparison of  $^{18}\text{F}$ -FDG PET/CT parameters did not highlight any  
44 significant difference in tumour glucose metabolism before and after the period of nutrition support.

45 ***Conclusions***

46 In cachexic patients with head and neck or oesophageal cancer, nutrition support administered  
47 according to the current guidelines shows no impact on tumour glucose metabolism, assessed by  $^{18}\text{F}$ -  
48 FDG PET/CT.

49 **Keywords:** Nutritional support; tumour growth;  $^{18}\text{F}$ -FDG PET/CT; cancer; cachexia; supportive care

## 50 INTRODUCTION

51 Cachexia is a common problem in patients with advanced cancer, especially oesophageal and  
52 head and neck cancer. In these patients, cachexia is correlated with an increase in therapy-related side  
53 effects and poorer response to treatment (cancer relapse, lower survival). European and national  
54 evidence-based guidelines have been published about nutritional support therapy in patients with  
55 cancer [1, 2]. Nutritional support, administered as recommended by these guidelines, has an impact on  
56 the patient outcome. However, it is not known whether artificial nutrition could “feed” the tumour and  
57 accelerate its growth. According to the European and French learned societies, the available proofs of  
58 a positive effect of artificial nutrition on tumour growth are not sufficient to recommend the  
59 suppression or delay of this therapy in cachectic patients with cancer. However, these  
60 recommendations are based on very few and quite old studies. Specifically, in 1991, Rossi-Fanelli *et*  
61 *al.* determined the thymidine labelling index in tumour samples collected before and after 14 days of  
62 glucose-based or lipid-based parenteral nutrition formula, or isocaloric oral diet (n=27 patients). They  
63 did not find a positive effect of glucose (or a negative effect of lipids) on cancer cell proliferation [3].  
64 Jin *et al.* assessed tumour cell growth (percentage of cells in S phase and DNA index) and sensitivity  
65 to chemotherapy in tumour samples from 91 patients with gastrointestinal cancer and malnutrition  
66 after 7 days of various preoperative interventions (parenteral nutrition alone, parenteral nutrition plus  
67 chemotherapy, chemotherapy alone, and no treatment) [4]. They found that the nutrition support and  
68 chemotherapy combination improved the patients’ short-term nutritional status without increasing  
69 tumour cell proliferation and prevented some adverse events observed in the group with chemotherapy  
70 alone. They also suggested, but without evidence, that parenteral nutrition improves chemotherapy  
71 effectiveness.

72 Recent imaging technologies allows investigating this crucial question in a non-invasive  
73 manner, by performing serial  $^{18}\text{F}$ -fluorodeoxyglucose (FDG) positron emission tomography/computed  
74 tomography ( $^{18}\text{F}$ -FDG PET/CT).  $^{18}\text{F}$ -FDG PET/CT imaging data are used to compute static and  
75 dynamic FDG parameters. Several studies have shown than dynamic FDG uptake measurements are  
76 more accurate than the standardized uptake value (SUV) to assess differences between benign and

77 tumour tissues and to highlight changes in tumour metabolism after treatment [5, 6]. Moreover, <sup>18</sup>F-  
78 FDG PET-based quantification of glucose metabolism is reproducible with a coefficient of variation  
79 of approximately 10% (test-retest studies for repeated scans of the same patients) [7]. Since glucose  
80 transport is the rate-limiting step of glycolysis in tumours, if artificial nutrition would have an effect  
81 on tumor activity, it would be by modifying tumor expression of glucose transporters (GLUTs) and  
82 hexokinases. Tumour mass changes are of a quite long duration and could not be detected  
83 quantitatively using the available methods (CT scan for example) in a short time period, contrary to  
84 tumour glucose metabolism which may be modified very quickly after treatment induction.

85 Therefore, we designed a prospective clinical study to determine whether artificial nutrition  
86 has an impact on tumour glucose metabolism in cachectic patients with cancer by comparing <sup>18</sup>F-FDG  
87 PET/CT static and dynamic imaging parameters before and after a period of nutrition support.

88

## 89 **METHODS**

### 90 *Study design and patients*

91 Inclusion criteria for this prospective study were: patients with histologically-proven head and  
92 neck or oesophageal cancer and cachexia (weigh loss >5%) and eligible for artificial (enteral or  
93 parenteral) nutrition supplementation; availability of one <sup>18</sup>F-FDG PET/CT exam performed at our  
94 centre before inclusion (standard procedure, outside this study); ≥18 years of age, and WHO (ECOG)  
95 performance status ≤2. The main exclusion criteria were: administration of a cancer treatment  
96 (chemotherapy, targeted therapy or surgery) in the past 2 months, or radiotherapy in the past 4 months;  
97 capillary blood glucose >12mmol/L at the first <sup>18</sup>F-FDG PET/CT evaluation; current treatment for  
98 diabetes (insulin or oral treatment); and contra-indication to <sup>18</sup>F-FDG PET/CT, such as pregnancy or  
99 breastfeeding, or psychological disorders. All patients signed a written informed consent prior to  
100 inclusion. The study was conducted in accordance with the Good Clinical Practice requirements  
101 (Helsinki Declaration), and was approved by local and national review boards. It was also registered  
102 on clinical.trials.gov.

103 ***Nutritional intervention***

104 Nutrition support therapy was administered in accordance with the French Clinical Nutrition  
105 and Metabolism Society guidelines [8]. Enteral and parenteral nutrition was adapted to the patient's  
106 current oral intake that was deduced from the 30-35cal/kg/day objective. Enteral nutrition was  
107 administered with a nasogastric probe. If enteral nutrition was not possible, parenteral nutrition was  
108 administered through a central venous catheter.

109 ***Assessment***

110 The intra-tumour metabolic glucose activity was evaluated using  $^{18}\text{F}$ -FDG PET/CT imaging at  
111 baseline (standard procedure) and after a minimum of 5 days of artificial nutrition. During this time,  
112 patients did not receive any cancer treatment. However, treatment initiation (*i.e.* chemotherapy) could  
113 not be delayed by the study. The patient food intake was measured using a visual analogue scale (food  
114 intake VAS) at baseline and at the second  $^{18}\text{F}$ -FDG PET/CT exam.

115 ***Glucose metabolism***

116 Glucose metabolism differs in normal and cancer cells. Specifically, normal cells produce  
117 energy from glucose mainly through the mitochondrial oxidative phosphorylation pathway.  
118 Conversely, cancer cells preferentially produce energy through conversion of glucose into lactate,  
119 even in aerobic conditions [9] (*i.e.*, aerobic glycolysis, also known as the "Warburg effect") [10]. To  
120 compensate for the poor energy production yield through the lactate pathway, glycolysis is increased  
121 in tumour cells through upregulation of GLUTs and glucose hexokinase. These transporters are not  
122 insulin-sensitive (unlike muscles) and therefore are not altered by glycaemia or a fasting period [11].

123  $^{18}\text{F}$ -FDG is a glucose analogue used as a PET radiotracer. Its uptake by tumour cells is directly  
124 related to their glucose consumption. Like glucose, it is transported into the cells, phosphorylated to  
125  $^{18}\text{F}$ -FDG-6-phosphate ( $^{18}\text{F}$ -FDG-6-P), and trapped within the cells. Therefore,  $^{18}\text{F}$ -FDG-PET imaging  
126 allows the direct estimation of the cancer cell glucose concentration and glycolytic activity.  $^{18}\text{F}$ -FDG-

127 PET is routinely used in oncology for the initial tumour detection, characterization and staging and for  
128 monitoring the therapeutic response in several cancer types [12].

### 129 ***Imaging***

130 Both  $^{18}\text{F}$ -FDG-PET and CT exams were performed using the same apparatus (Discovery  
131 PET/CT 690 scan, GE Healthcare, Milwaukee, Wisconsin, USA) [13], in the same conditions, and  
132 approximatively ( $\pm 2$  hours) at the same time of the day. Patients were asked to strictly fast during the  
133 6 hours before  $^{18}\text{F}$ -FDG injection and artificial nutrition was also stopped. After intravenous injection  
134 of 3.5MBq/kg  $^{18}\text{F}$ -FDG, dynamic PET images centred on the tumour were acquired for 40 minutes,  
135 followed by static whole-body images at 60 minutes after  $^{18}\text{F}$ -FDG injection. Images were acquired  
136 using the *List Mode*, corrected (for normalization, dead time, activity decay, random coincidence,  
137 attenuation and scatter) and then reconstructed in a 256x256 image matrix. The acquired field of view  
138 size was 70 cm. Image analysis was performed using the PMOD software. For all patients, the region  
139 of interest (ROI) was drawn around the primary tumour by the same experimented nuclear medicine  
140 physician to calculate the imaging parameters. SUV is the most commonly used parameter for glucose  
141 metabolism quantification, and represents the FDG concentration in a volume of interest (*i.e.*, the  
142 tumour or part of the tumour) normalized to the patient's weight and total injected activity:

$$143 \quad \text{SUV} = \frac{\text{activity concentration in tissue}}{(\text{injected activity} / \text{body weight})}$$

144 On static 3D PET images (acquired 60 minutes after  $^{18}\text{F}$ -FDG injection), the following parameters  
145 were extracted from the ROI within the tumour:

- 146 - **SUV<sub>max</sub>**: the voxel with the highest radioactivity within the ROI; is the most widely used  
147 parameters with good inter-observer reproducibility;
- 148 - **SUV<sub>mean</sub>**: reflects the metabolic activity within the whole tumour; however, it is sensitive to  
149 the tumour volume delineation;
- 150 - **SUL<sub>peak</sub>** (SUL = SUV normalized to the lean body mass): represents the average activity in a  
151 small fixed-size ROI that includes the maximum voxel; this is considered to be the best  
152 parameter for the assessment of solid cancer response to treatment [12].

153  $SUV_{mean}$  and  $SUV_{max}$  were also assessed in peritumoral healthy tissue.

154 To reflect variations over time, the dynamic PET (dPET) images acquired just after  $^{18}F$ -FDG injection

155 were used to calculate the following parameters. The glucose metabolic rate (**MRGlu**, expressed in

156  $\mu\text{mol}\cdot\text{min}^{-1}\cdot 100\text{g}^{-1}$  of tumour tissue) was calculated using the “MRGlu Patlack” mode of the PMOD

157 software, as previously described [14]. The vascular input function was set on an artery found in the

158 view field, and the lump constant (LC) was set to 1. Another PMOD mode (“the two-compartment”

159 mode) allowed calculating **the transport constant rates (k)** of the two-compartment model


160 (Figure 1):  $k_1$ ,  $k_2$ ,  $k_3$ ,  $k_4$  (expressed in  $\text{h}^{-1}$ ). These variables are associated with molecular biological

161 processes, such as GLUT ( $k_1$ - $k_2$ ) and hexokinase activities ( $k_3$ - $k_4$ ). The PET/CT device quantitative

162 accuracy was assessed following the European guidelines for  $^{18}F$ -FDG PET/CT tumour imaging [15],

163 and the device was accredited for tumour imaging by the European Association of Nuclear Medicine

164 Research Ltd (EARL).



165

166 **Figure 1:** Two-compartment model of FDG kinetics in tumour cells



167 ***Endpoints***

168           The primary endpoint was the difference between pre- and post-artificial nutrition intra-  
169 tumour SUV<sub>max</sub> values. Secondary endpoints were the pre- and post-artificial nutrition variations of the  
170 static parameters SUV<sub>mean</sub> and SUL<sub>peak</sub>, and of the dynamic parameters MRGlu, k<sub>1</sub>, k<sub>2</sub>, k<sub>3</sub>, and k<sub>4</sub>.

171 ***Statistical analysis***

172           Continuous variables were described using medians and ranges, and categorical variables  
173 with frequencies and percentages. The Wilcoxon Rank-Sum test was used to compare the distribution  
174 of continuous variables between the first and second <sup>18</sup>F-FDG PET/CT exam. All tests were two-sided  
175 and a *p*-value <0.05 was considered as statistically significant. Statistical analyses were performed  
176 using STATA 13.0 (StataCorp, College Station, TX, USA).

177

178 **RESULTS**

179 ***Patients***

180           Eleven patients were included in our prospective monocentric study (Table 1). Among them, 9  
181 (81.8%) were men. The median age was 61 years [range: 52-74], and the WHO (ECOG) performance  
182 status score ranged between 0 (n=4, 36.4%) and 1 (n=7, 63.6%). Three patients (27.3%) had head and  
183 neck, and eight (72.7%) oesophageal cancers. None of the patients received any cancer treatment prior  
184 to inclusion in this study, but all patients were intended to be curatively treated. The median duration  
185 between cancer diagnosis and inclusion in the trial was 19.5 days [7-46].

186           The patients' median weight loss was 4.05% (0.6-6.1) at 1 month and 10.8% (7.3-34) at 6  
187 months post-diagnosis. One patient was excluded from the study after the first <sup>18</sup>F-FDG PET/CT  
188 because he required oesophageal dilatation and stent that could induce inflammation and, thus, bias the  
189 analysis results.

Baseline characteristics	n=11
Sex, n (%)	
Men	9 (81.8)
Women	2 (18.2)
Age (years), median [range]	61 [52-74]
WHO performance status	
0	4 (36.4)
1	7 (63.6)
Weight loss at 1 month (%), median [range]	4.05 [0.6-6.1]
Weight loss at 6 months (%), median [range]	10.8 [7.3-34]
Body mass index (kg/m <sup>2</sup> )	21 [16-27.8]
Previous treatment	None
Primary tumour localization, n (%)	
Head and neck	3 (27.3)
Oesophagus	8 (72.7)
Nutritional status	
Baseline Food intake VAS (/10), median [range]	3 [0-6]
Artificial nutrition	
Yes	10 (100)
Missing	1
Artificial energy intake (kcal/kg/day), median [range]	21.83 [13.16-45.90]
Including proteins (g/kg/day), median [range]	0.84 [0.56-1.64]
Artificial nutrition type	
Enteral	8 (80)
Parenteral	2 (20)
Missing	1
Duration of artificial nutrition (days), median [range]	7 [5-9]
Oral nutrition	
Yes	10 (100)
Missing	1
Oral energy intake (kcal/kg/day), median [range]	19.44 [5.37-25.95]
Including proteins (g/kg/day), median [range]	0.63 [0.11-3.64]
Food intake VAS (/10) at PET2, median [range]	5 [1-10]

WHO: World Health Organization; VAS: Visual Analogue Scale; kcal: kilocalories

191 ***Nutritional status***

192 The baseline median food intake VAS score was 3 [0-6]. Artificial nutrition was administered  
 193 to 10 patients (median energy intake: 21.83 kcal/kg/day [13.16-45.90], with a median protein intake of  
 194 0.84 g/kg/day [0.56-1.64]) (Table 1). Artificial nutrition (enteral for eight patients, 80%, and  
 195 parenteral for two patients, 20%) was used to complement oral nutrition (median oral energy intake:  
 196 19.44 kCal/kg/day [5.37-25.95]). On average, patients received artificial nutrition for 7 days ([5-9])  
 197 before the second <sup>18</sup>F-FDG PET/CT exam. The food uptake VAS score was 5 [1-10] at second  
 198 PET/CT, higher than that at baseline evaluation, although it was not significant ( $p=0.13$ ).

199 ***Metabolic <sup>18</sup>F-FDG PET/CT data***

200 The values of all the tumour glucose metabolism parameters (static and dynamic) were not  
 201 significantly different between first and second <sup>18</sup>F-FDG PET/CT (Table 2 and Figure 2). Specifically,  
 202 the pre- and post-artificial nutrition mean SUV<sub>max</sub> scores (primary outcome) were comparable (11.0  
 203 [7.8-22.2] and 10.2 [7.3-20.6]). There was also no significant difference in SUV<sub>mean</sub> and SUV<sub>max</sub> in  
 204 peritumoral tissue between the first and second <sup>18</sup>F-FDG PET/CT (Table 2).

205


	PET/CT 1	PET/CT 2	<i>p</i> -value
Body weight just before <sup>18</sup> F-FDG injection (kg), median [range]	65.9 [30-83]	66.0 [31-83]	1
Blood glucose level (g.L <sup>-1</sup> ) just before <sup>18</sup> F-FDG injection, median [range]	1 [0.7-1.1]	1.1 [0.9-1.3]	1
Median time between nutrition delivery and PET/CT (hours)		8.37 [6.50-15.12]	
<b>Tumoral FDG uptake</b>			
SUV <sub>max</sub> (g/mL), median [range]	11.0 [7.8-22.2]	10.2 [7.3-20.6]	0.7
SUV <sub>mean</sub> (g/mL), median [range]	6.4 [4.3-12.9]	6.1 [3.9-12.2]	1
SUL <sub>peak</sub> (g/mL), median [range]	8.8 [6.8-18.8]	8.6 [5.5-17.4]	0.76
MRGlu (μmol.min <sup>-1</sup> .100g <sup>-1</sup> ), median [range]	32.2 [10.3-77.1]	35 [11.6-88.5]	0.63
k <sub>1</sub> (h <sup>-1</sup> ), median [range]	0.4 [0.19-0.67]	0.4 [0.1-0.95]	0.82

$k_2$ ( $\text{h}^{-1}$ ), median [range]	0.6 [0.42-0.78]	0.5 [0.18-0.78]	0.5
$k_3$ ( $\text{h}^{-1}$ ), median [range]	0.1 [0.03-0.21]	0.1 [0.03-0.17]	0.4
$k_4$ ( $\text{h}^{-1}$ ), median [range]	0 [0-0]	0 [0-0.06]	0.69
<b>Peritumoral FDG uptake</b>			
$\text{SUV}_{\text{mean}}$ (g/mL), median [range]	1.5 [0.8-2.7]		
$\text{SUV}_{\text{max}}$ (g/mL), median [range]	2 [1.3-3.8]		

FDG:  $^{18}\text{F}$ -Fluorodeoxyglucose, SUV: Standardized Uptake Value; SUL: Standardized Uptake Value corrected for Lean Body Mass, MRGlu: Metabolic Rate of Glucose

206

207 **Table 2:** Glucose metabolism parameters at the first and second  $^{18}\text{F}$ -FDG PET/CT



208

209 **Figure 2:** Representative  $^{18}\text{F}$ -FDG PET/CT images centred on the oesophageal cancer at baseline  
 210 (PET/CT 1) and after 9 days of artificial nutrition (PET/CT 2) showing the absence of visual  
 211 differences in  $^{18}\text{F}$ -FDG uptake (images acquired 60 minutes after  $^{18}\text{F}$ -FDG injection)

212

## 213 **DISCUSSION**

214 In this study we show that artificial nutrition in patients with head and neck and oesophageal  
 215 cancer has no impact on tumour glucose metabolism, assessed by  $^{18}\text{F}$ -FDG PET/CT (both static  
 216 dynamic PET parameters). This is, to our knowledge, the first clinical study that studied the impact of  
 217 standard nutritional support (for a mean of 7 days) using non-invasive visualization of tumour glucose  
 218 metabolism by  $^{18}\text{F}$ -FDG PET.

219 In 2004, Bozetti *et al.* performed a study with  $^{18}\text{F}$ -FDG PET/CT in 12 patients with liver  
220 metastases from colorectal cancer [16]. They investigated the effect of the administration of glucose-  
221 or lipid-based total parenteral nutrition (4 mg/kg/min glucose, or 2 mg/kg/min lipids and 0.7  
222 mg/kg/min amino acids) for three hours before  $^{18}\text{F}$ -FDG PET/CT, compared with control (fasting  
223 without glucose/lipid infusion). They did not find any significant change in the SUV score of liver  
224 metastases. However, this study assessed the immediate effect of a short load of glucose or lipid [16],  
225 whereas our present work evaluated the impact of a longer nutritional support (at least 5 days). The  
226 reviews by Bozetti *et al.* and by Bossola *et al.* [17, 18] identified only few studies (controlled or not)  
227 on the impact of nutritional interventions on tumour growth. In all these studies, the number of  
228 patients was small (n=10 to 20), and the definition of malnutrition and of cachexia heterogeneous.  
229 Moreover, in most of them, tumour growth was assessed based on cancer cell cycle kinetic parameters  
230 (DNA index, DNA distribution by flow cytometry, labelling index with tritiated thymidine or  
231 bromodeoxyuridine). Among the five controlled and randomized studies (nutritional support for 6 to  
232 18 days) [4, 19-22], only two reported an increase in tumour cell proliferation following artificial  
233 nutrition [4, 19]. These reviews concluded that there is no evidence for an effect of nutritional support  
234 on tumour growth. In agreement, the European guidelines state that "theoretical arguments that  
235 nutrients "feed the tumour" are not supported by evidence related to clinical outcome and should not  
236 be used to refuse, diminish or stop feeding". Since the studies by Rossi-Fanelli [3] and Jin [4] quoted  
237 in the European guidelines, imaging techniques and nutritional support guidelines have changed.  
238 Nevertheless, we found surprising that studies on this topic are quite rare, especially now when  
239 dieticians and nutritionists are involved in the management of patients with cancer. On the other hand,  
240 recent publications have evaluated the link between fasting and tumour cell sensitivity to  
241 chemotherapy [23]. A recent comprehensive review of all literature data (many animal studies and few  
242 epidemiological and clinical studies) ([https://www6.inra.fr/nacre/Le-reseau-NACRe/Publications/  
243 Rapport-NACRe-jeune-regimes-restrictifs-cancer-2017](https://www6.inra.fr/nacre/Le-reseau-NACRe/Publications/Rapport-NACRe-jeune-regimes-restrictifs-cancer-2017)) concluded that there is no evidence that  
244 fasting and restrictive diets (i.e., intermittent fasting, caloric restriction and ketogenic diets) have any  
245 effect (beneficial or deleterious) on cancer prevention and treatment. FDG tumour uptake may be  
246 influenced by lactate levels in tumours ([24]), and Schroeder *et al.* showed that a ketogenic diet (which

247 differs in terms of carbohydrate intake from the artificial nutrition delivered in our study) decreased  
248 tumour lactate levels in patients with head and neck cancer [25]. A difference in our outcome  
249 parameters could have been linked to the tumour lactate levels. Plasma glucose levels were identical  
250 for PET1 and PET2. However, as tumours are not insulin-dependent tissues, a difference in plasma  
251 glucose level at PET1 and PET2 would probably have no impact on our results.

252 The small number of patients, although in the range of the previously published studies, is a  
253 limitation of our study. The lack of significant differences between PET1 and PET2 may be caused by  
254 the small size of the studied cohort. We had planned to include 20 patients, but accrual was difficult  
255 mainly due to the protocol requirements: (i) organizing in a very short time both nutritional support  
256 and a second  $^{18}\text{F}$ -FDG PET/CT to ensure no delay in treatment initiation; and (ii) most potentially  
257 eligible patients had already undergone  $^{18}\text{F}$ -FDG PET/CT imaging before arrival in our centre.  
258 Performing three  $^{18}\text{F}$ -FDG PET/CT scans, which would have allowed patient inclusion, was not  
259 acceptable. Other limitations are the relatively short period of nutritional support (median = 7 days)  
260 before the second  $^{18}\text{F}$ -FDG PET/CT (due to the organizational constraints described above and  
261 because it was not acceptable to delay patients cancer therapy initiation), and the inclusion only of  
262 patients with head and neck or oesophageal cancer only because  $^{18}\text{F}$ -FDG PET/CT is performed at  
263 diagnosis as standard practice.

264 In conclusion, our clinical study did not find any effect of artificial nutrition on tumour  
265 metabolism assessed with  $^{18}\text{F}$ -FDG PET/CT in cachectic patients with head and neck or oesophageal  
266 cancer. Patients all received artificial nutrition according to the current guidelines in order to ensure  
267 the best support to reduce side-effects, and to satisfy the nutritional requirements of patients with  
268 cancer.

269

## 270 **ACKNOWLEDGEMENTS**

271 The authors thank the patients and their families for their participation in the study. They also thank  
272 Lobna Rifai and Caroline Constant for their work as project manager and clinical research assistant,

273 Mathieu Depetris for datamanagement, and Julie Courraud for her help with the study design. This  
274 research was supported by the SIRIC Montpellier Cancer Grant INCa\_Inserm\_DGOS\_12553.

275

## 276 **STATEMENT OF AUTHORSHIP**

277 All persons who meet authorship criteria are listed as authors, and all authors certify that they have  
278 participated sufficiently in the work to take public responsibility for the content, including  
279 participation in the concept, design, analysis, writing, or revision of the manuscript.

280

## 281 **FUNDING SOURCES**

282 This investigator-initiated trial was funded by the APARD foundation. The study funder had no role in  
283 the design and conduct of the study; collection, management, analysis, and interpretation of the data;  
284 preparation, review, or approval of the manuscript; or decision to submit the manuscript for  
285 publication.

286

## 287 **COMPETING INTERESTS STATEMENT**

288 The authors have no conflict of interest to disclose regarding the present study.

289

## 290 **REFERENCES**

- 291 1. Arends, J., et al., *ESPEN guidelines on nutrition in cancer patients*. Clinical Nutrition, 2017.  
292 **36**(1): p. 11-48.
- 293 2. Senesse, P., P. Bachmann, and R. Bensadoun, *Clinical nutrition guidelines of the French*  
294 *Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of*

- 295            *recommendations for adults undergoing non-surgical anticancer treatment. Dig Liver Dis,*  
296            2014. **46**(8): p. 667-74.
- 297    3.    Rossifanelli, F., et al., *Effect of energy substrate manipulation on tumour cell proliferation in*  
298            *parenterally fed cancer patients. Clinical Nutrition, 1991. 10*(4): p. 228-232.
- 299    4.    Jin, D., M. Phillips, and J.E. Byles, *Effects of parenteral nutrition support and chemotherapy*  
300            *on the phasic composition of tumor cells in gastrointestinal cancer. JPEN J Parenter Enteral*  
301            *Nutr, 1999. 23*(4): p. 237-41.
- 302    5.    Dimitrakopoulou-Strauss, A., L. Pan, and L.G. Strauss, *Quantitative approaches of dynamic*  
303            *FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients. Cancer*  
304            *Imaging, 2012. 12*: p. 283-9.
- 305    6.    Epelbaum, R., et al., *Tumor aggressiveness and patient outcome in cancer of the pancreas*  
306            *assessed by dynamic 18F-FDG PET/CT. J Nucl Med, 2013. 54*(1): p. 12-8.
- 307    7.    Lodge, M.A., *Repeatability of SUV in Oncologic 18F-FDG PET. J Nucl Med, 2017. 58*(4): p.  
308            523-532.
- 309    8.    Crenn, P., et al., *SFNEP oncology nutrition guidelines: Place of artificial nutrition in the*  
310            *management of cancer patients. Nutrition Clinique et Métabolisme, 2012. 26*(4): p. 278-295.
- 311    9.    Warburg, O., *On the origin of cancer cells. Science, 1956. 123*(3191): p. 309-14.
- 312    10.    Vander Heiden, M.G., L.C. Cantley, and C.B. Thompson, *Understanding the Warburg Effect:*  
313            *The Metabolic Requirements of Cell Proliferation. Science (New York, N.Y.), 2009.*  
314            **324**(5930): p. 1029-1033.
- 315    11.    Busing, K.A., et al., *Impact of blood glucose, diabetes, insulin, and obesity on standardized*  
316            *uptake values in tumors and healthy organs on 18F-FDG PET/CT. Nucl Med Biol, 2013.*  
317            **40**(2): p. 206-13.
- 318    12.    Wahl, R.L., et al., *From RECIST to PERCIST: Evolving Considerations for PET response*  
319            *criteria in solid tumors. J Nucl Med, 2009. 50 Suppl 1*: p. 122S-50S.
- 320    13.    Bettinardi, V., et al., *Physical performance of the new hybrid PETCT Discovery-690. Med*  
321            *Phys, 2011. 38*(10): p. 5394-411.



- 322 14. Patlak, C.S. and R.G. Blasberg, *Graphical evaluation of blood-to-brain transfer constants*  
323 *from multiple-time uptake data. Generalizations.* J Cereb Blood Flow Metab, 1985. **5**(4): p.  
324 584-90.
- 325 15. Boellaard, R., et al., *FDG PET/CT: EANM procedure guidelines for tumour imaging: version*  
326 *2.0.* Eur J Nucl Med Mol Imaging, 2015. **42**(2): p. 328-54.
- 327 16. Bozzetti, F., et al., *Glucose-based total parenteral nutrition does not stimulate glucose uptake*  
328 *by humans tumours.* Clin Nutr, 2004. **23**(3): p. 417-21.
- 329 17. Bossola, M., et al., *Does nutrition support stimulate tumor growth in humans?* Nutr Clin  
330 Pract, 2011. **26**(2): p. 174-80.
- 331 18. Bozzetti, F. and V. Mori, *Nutritional support and tumour growth in humans: a narrative*  
332 *review of the literature.* Clin Nutr, 2009. **28**(3): p. 226-30.
- 333 19. Bozzetti, F., et al., *Total parenteral nutrition and tumor growth in malnourished patients with*  
334 *gastric cancer.* Tumori, 1999. **85**(3): p. 163-166.
- 335 20. Dionigi, P., et al., *Pre-operative nutritional support and tumour cell kinetics in malnourished*  
336 *patients with gastric cancer.* Clin Nutr, 1991. **10** **Suppl**: p. 77-84.
- 337 21. Edstrom, S., et al., *Cell cycle distribution and ornithine decarboxylase activity in head and*  
338 *neck cancer in response to enteral nutrition.* European Journal of Cancer & Clinical  
339 Oncology, 1989. **25**(2): p. 227-232.
- 340 22. Pacelli, F., et al., *Parenteral nutrition does not stimulate tumor proliferation in malnourished*  
341 *gastric cancer patients.* JPEN J Parenter Enteral Nutr, 2007. **31**(6): p. 451-5.
- 342 23. Laviano, A. and F. Rossi Fanelli, *Toxicity in chemotherapy--when less is more.* N Engl J Med,  
343 2012. **366**(24): p. 2319-20.
- 344 24. Zhou, X., et al., *Relationship between 18F-FDG accumulation and lactate dehydrogenase A*  
345 *expression in lung adenocarcinomas.* J Nucl Med, 2014. **55**(11): p. 1766-71.
- 346 25. Schroeder, U., et al., *Decline of lactate in tumor tissue after ketogenic diet: in vivo*  
347 *microdialysis study in patients with head and neck cancer.* Nutr Cancer, 2013. **65**(6): p. 843-9.
- 348

349 **FIGURE AND TABLE LEGENDS**

350 **Table 1:** Patients' characteristics at baseline and nutritional status

351 **Table 2:** Glucose metabolism parameters at the first and second  $^{18}\text{F}$ -FDG PET/CT

352 **Figure 1:** Two-compartment model of FDG kinetics in tumour cells

353 **Figure 2:** Representative  $^{18}\text{F}$ -FDG PET/CT images centred on the oesophageal cancer at baseline  
354 (PET/CT 1) and after 9 days of artificial nutrition (PET/CT 2) showing the absence of visual  
355 differences in  $^{18}\text{F}$ -FDG uptake (images acquired 60 minutes after  $^{18}\text{F}$ -FDG injection)